Drug Profile


Alternative Names: Can-C; NAC - Innovative Vision Products; Nu-Eyes

Latest Information Update: 18 Jul 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innovative Vision Products
  • Class Dipeptides; Eye disorder therapies; Neuropeptides
  • Mechanism of Action Antioxidants; Glycosylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Cataracts
  • Phase Unknown Eye-Disorders

Most Recent Events

  • 18 Jul 2006 Launched for Cataracts in World (Ophthalmic)
  • 18 Jul 2004 Investigation in Eye disorders in USA (Ophthalmic)
  • 16 Apr 2002 Clinical trials in Cataracts in Russia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top